Antinociceptive and antidepressant-like profiles of BL-2401, a novel enkephalinase inhibitor, in mice and rats

Japanese Journal of Pharmacology

Volumn 75, Issue 4, 1997, Pages 337-346

  Kita, Atsuko ^a   Imano, Kiyomi ^a   Seto, Yasuhiro ^a   Yakuo, Ikuhisa ^a   Deguchi, Takashi ^a   Nakamura, Hideo ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antidepressant like action; Antinociception; BL 2401; Enkephalinase inhibitor; Opioid

Indexed keywords

3 (2 BENZYL 3 MERCAPTOPROPIONAMIDO) 5 METHYLBENZOIC ACID; 3 [2 BENZYL 3 (PROPIONYLTHIO)PROPIONAMIDO] 5 METHYLBENZOIC ACID; ANTIDEPRESSANT AGENT; BRAIN ENZYME; CODEINE PHOSPHATE; ENKEPHALINASE INHIBITOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE]; MEMBRANE METALLOENDOPEPTIDASE; NALOXONE; OPIATE RECEPTOR; PHENYLQUINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENCY; ENZYME INHIBITION; FEMALE; FORCED SWIMMING TEST; HOT PLATE TEST; HYPERALGESIA; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; WRITHING TEST;

EID: 0031460601     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.75.337     Document Type: Article

References (35)

1. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA and Morris HR: Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258, 577-579 (1975)
2. Martin WR: Pharmacology of opioids. Pharmacol Rev 35, 283-323 (1983)
3. Olson GA, Olson RD and Kastin AJ: Endogenous opiates: 1994 Peptides 16 1517-1555 (1995)
4. Minami M and Satoh M: Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res 23, 121-145 (1995)
5. Horwell DC: Kappa opioid analgesics. Drugs of the Future 13, 1061-1071 (1988)
6. Roques BP, Beaumont A, Dauge V and Fournié-Zaluski MC: Peptidase inactivation of enkephalins: Design of inhibitors and biochemical, pharmacological and clinical application. In Handbook of Experimental Pharmacology, Vol 104/I, Opioids I, Edited by Herz A, pp 547-584, Springer-Verlag, Berlin (1993)
7. Schwartz JC: Metabolism of enkephalins and the inactivating neuropeptidase concept. Trends Neurosci 6, 45-48 (1983)
8. Chipkin RE: Inhibitors of enkephalinase: the next generation of analgesics. Drugs of the Future 11, 593-606 (1986)
9. Nabeshima T, Katoh A and Kameyama T: Inhibition of enkephalin degradation attenuated stress-induced motorsupression (conditioned suppression of motility). J Pharmacol Exp Ther 244, 303-309 (1988)
10. Katoh A, Nabeshima T and Kameyama T: Behavioral changes induced by stressful situations: Effects of enkephalins, dynorphin, and their interactions. J Pharmacol Exp Ther 253, 600-607 (1990)
11. Lecomte JM, Costentin J, Vlaiculescu A, Chaillet P, Marcais-Collado H, Llorens-Cortes C, Leboyer M and Schwartz J-C: Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor. J Pharmacol Exp Ther 237, 937-944 (1986)
12. 1 receptor stimulation Eur J Pharmacol 216, 157-166 (1992)
13. Roques BP, Fournié-Zaluski M-C, Soroca E, Lecomte JM, Malfloy B, Llorens C and Schwartz J-C: The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288, 286-288 (1980)
14. Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournie-Zaluski MC and Roques BP: Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261, 181-190 (1992)
15. Chipkin RE, Berger JG, Billard W, Iorio LC, Chapman R and Barnett A: Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic. J Pharmacol Exp Ther 245, 829-838 (1988)
16. Foong FW, Nakagawa N, Katsube N, Aishita H, Okegawa T and Kawasaki A: A novel enkephalinase inhibitor as an orally active analgesic. Pain Suppl 5, S198 (1990)
17. Mimura T, Nakamura Y, Nishino J, Sawayama T, Komiya T, Deguchi T, Kita A, Nakamura H and Matsumoto J: A novel class of enkephalinase inhibitors containing a C-terminal sulfo group. J Med Chem 35, 602-608 (1992)
18. Dworkin RH and Gitlin MJ: Clinical aspects of depression in chronic pain patients Clin J Pain 7, 79-94 (1991)
19. Siegmund E, Cadmus R and Lu G: A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med 95, 729-731 (1957)
20. Nakamura H, Ishii K, Yokoyama Y, Imazu C, Shimoda A, Kadokawa T and Shimizu M: Central actions of AD-1211, an analgesic lacking common opiate features. Eur J Pharmacol 106, 345-356 (1984)
21. Litchfield JT and Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96, 99-113 (1949)
22. Ueda H, Amano H, Shiomi H and Takagi H: Comparison of the analgesic effects of various opioid peptides by a newly devised intracisternal injection technique in conscious mice. Eur J Pharmacol 56, 265-268 (1979)
23. Niemegeers CJE, Van Bruggen JAA and Janssen PAJ: Suprofen, a potent antagonist of acetic acid-induced writhing in rats. Arzneimittelforschung 25, 1505-1509 (1975)
24. Nakamura H and Shimizu M: Comparative study of 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine and its enantiomorphs on analgesic and other pharmacological activities in experimental animals. Arch Int Pharmacodyn Ther 221, 105-121 (1976)
25. Eddy NB and Leimbach D: Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Ther 107, 385-393 (1953)
26. Porsolt RD, Bertin A and Jalfre M: Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn 229, 327-336 (1977)
27. Gorenstein C and Snyder SH: Two distinct enkephalinases: solubilization, partial purification and separation from angiotensin converting enzyme. Life Sci 25, 2065-2070 (1979)
28. Vogel Z and Alstein M: The adsorption of enkephalin to porous polystyrene beads: a simple assay for enkephalin hydrolysis. FEBS Lett 80, 332-336 (1977)
29. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Polin phenol reagent. J Bio Chem 193, 265-275 (1951)
30. Nakamura H, Yokoyama Y, Motoyoshi S, Ishii K, Imazu C, Seto Y, Kadokawa T and Shimizu M: The pharmacological profile of 2-(8-methyl-10,11-dihydro-1-oxidibenz[b,f]oxepin-2-yl)propionic acid (AD-1590), a new non-steroidal anti-inflammatory agent with potent antipyretic activity. Arzneimittelforschung 33, 1555-1569 (1983)
31. Dray A, Urban L and Dickenson A: Pharmacology of chronic pain. Trends Pharmacol Sci 15, 190-197 (1994)
32. Markenson JA: Mechanisms of chronic pain. Am J Med 101, Suppl 1A, 6S-18S (1996)
33. Katz WA: Approach to the management of nonmalignant pain. Am J Med 101, Suppl 1A, 54S-63S (1996)
34. Costentin J, Vlaiculescu A, Chaillet P, Natan LB, Aveaux D and Schwartz J-C: Dissociated effects of inhibitors of enkephalin-metabolizing peptidase or naloxone on various nociceptive responses. Eur J Pharmacol 123, 37-44 (1986)
35. Cesselin F, Le Bars D, Bourgoin S, Artaud F, Gozlan H, Clot AM, Besson JM and Hamon M: Spontaneous and evoked release of methionine-enkephalin-like material from the rat spinal cord in vivo. Brain Res 339, 305-313 (1985)